Martin-Luther-Universität Halle-Wittenberg

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Private

Established: 1502-01-01

Employees: -

Market Cap: -

Website: http://www.uni-halle.de

Clinical Trials

PiA: Prognosis Used Every Day for Patients With Operable Breast Cancer - Comparison of Invasion Factors uPA/PAI-1 With Other Prognostic Factors

Conditions: Breast Cancer

First Posted Date: 2012-05-07

Last Posted Date: 2017-06-26

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 1000

Registration Number: NCT01592825

Assessment of Target Site Pharmacokinetics of Voriconazole in Healthy Volunteers During Sequence Therapy

Phase 4

Completed

Conditions: Healthy

First Posted Date: 2012-02-27

Last Posted Date: 2013-11-01

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 9

Registration Number: NCT01539330

Locations: 🇦🇹
Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents

Phase 2

Terminated

Conditions: Gliomas

Interventions: Drug: Cilengitide
Drug: Temozolomide

First Posted Date: 2012-01-25

Last Posted Date: 2015-07-21

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 28

Registration Number: NCT01517776

Locations: 🇩🇪
University Children´s Hospital, Halle, Saxonia-Anhalt, Germany

Effect of Vitamin D3 on Cardiovascular Risk Factors

Not Applicable

Completed

Conditions: Hypertensive Disease
Deficiency of Vitamin D3

Interventions: Dietary Supplement: Placebo
Dietary Supplement: Vitamin D3

First Posted Date: 2011-12-30

Last Posted Date: 2018-10-11

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 250

Registration Number: NCT01501916

CD16+ Monocytes in Coronary Heart Disease (CHD)

Completed

Conditions: Coronary Heart Disease

First Posted Date: 2011-09-29

Last Posted Date: 2011-09-29

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 1000

Registration Number: NCT01442948

Locations: 🇩🇪
University Clinic of the Martin Luther-University Halle-Wittenberg, Halle (Saale), Please Select, Germany

TRICC-C (AIO-KRK-0111): BIBF 1120 Versus Placebo in Patients Receiving Oxaliplatin Plus Fluorouracil and Leucovorin (mFOLFOX6) for Advanced, Chemorefractory Metastatic Colorectal Cancer (mCRC)

Phase 2

Completed

Conditions: Colorectal Cancer

Interventions: Drug: mFOLFOX6 + BIBF 1120
Drug: mFOLFOX6+placebo

First Posted Date: 2011-05-30

Last Posted Date: 2019-09-19

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 54

Registration Number: NCT01362361

Locations: 🇩🇪
Universitätsklinikum Greifswald -Klinik für Innere Medizin A, Greifswald, Germany
🇩🇪
Stauferklinikum Schwäbisch Gmünd - Mutlangen - Zentrum Innere Medizin, Mutlangen, Germany
🇩🇪
Universitätsklinikum Ulm - Klinik für Innere Medizin I, Ulm, Germany

and more 9 locations

Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-

Phase 2

Completed

Conditions: Colorectal Serrated Adenomas
Colorectal Tubulovillous Adenomas
Colorectal Tubular Adenomas
Colorectal Villous Adenomas

Interventions: Dietary Supplement: Green tea extract of Camellia Sinensis
Dietary Supplement: Green tea extract of Camellia Sinensis followed by placebo

First Posted Date: 2011-05-25

Last Posted Date: 2019-09-20

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 1001

Registration Number: NCT01360320

Locations: 🇩🇪
Regio Kliniken Pinneberg, Pinneberg, Germany
🇩🇪
Dr. Zeisler, Praxis für Innere Medizin und Gastroenterologie, Halle, Germany
🇩🇪
Dr. Frank-Gleich Praxis für Innere Medizin und Gastroenterologie, Halle, Germany

and more 18 locations

Efficacy of FOLFOX+Bevacizumab in Combination With Irinotecan in the Treatment of Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Metastatic Colorectal Cancer

Interventions: Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
Drug: Oxaliplatin, 5FU/LV, Bevacizumab

First Posted Date: 2011-03-24

Last Posted Date: 2018-10-25

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 250

Registration Number: NCT01321957

Locations: 🇩🇪
Klinikum Heidenheim, Heidenheim, Germany
🇩🇪
Medizinische Klinik mit Schwerpunkt Hämatologie und Onkologie, Berlin, Germany
🇩🇪
Onkologische Praxis, Bottrop, Germany

and more 48 locations

Multiple Symptoms in Cancer Patients a Cross Sectional Multi Center Study

Completed

Conditions: Cancer

First Posted Date: 2011-03-17

Last Posted Date: 2012-09-27

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 697

Registration Number: NCT01317355

Locations: 🇩🇪
Department for Health and Nursing Science, Medical Faculty, Martin-Luther-University Halle-Wittenberg, Halle, Saxony-Anhalt, Germany

Circadian Rhythm of Blood Lactate

Completed

Conditions: Healthy

Interventions: Other: Blood Sampling

First Posted Date: 2011-02-25

Last Posted Date: 2012-05-02

Lead Sponsor: Martin-Luther-Universität Halle-Wittenberg

Target Recruit Count: 30

Registration Number: NCT01303848

Locations: 🇩🇪
University Clinic Halle, Martin Luther-University Halle-Wittenberg, Halle (Saale), Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy